Cryptic MERS-CoV Cases in Saudi Arabia Raise Exposure Ascertainment Concerns

More than a decade after Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia, the virus remains a zoonotic threat with epidemic potential. Dromedary camels are the principal animal reservoir, and human infection occurs through direct or indirect exposure to infected camels, contaminated environments, or camel-derived products. Between March and September 2026, eight laboratory-confirmed MERS-CoV cases were reported in the Kingdom, and the epidemiological pattern of this small cohort carries lessons that extend well beyond its size. Most patients had major comorbidities, the majority reported no known camel exposure, and cases occurred across geographically dispersed regions, reinforcing that low reported case counts do not signify the absence of risk in a region where the camel-human interface remains active and health-care-associated amplification remains possible. These observations extend the persistent signals described in 2025, when sporadic MERS-CoV detections revealed continuing gaps in surveillance, clinical recognition, and preparedness.

The eight cases were distributed across six locations: Al Jouf, Taif, Hafr Al-Batin, Riyadh, Tabuk, and Arar. Two cases were reported in Riyadh and two in Taif, while the remaining cases occurred in geographically separate northern, northeastern, and northwestern regions. This dispersion is inconsistent with a single localized cluster and instead suggests repeated independent introductions, unrecognized exposures, or both. The cohort was predominantly male, with seven of the eight patients being male, and four patients were aged 70 years or older. Seven patients had comorbidities, features consistent with the established severity profile of MERS-CoV, in which advanced age and chronic cardiopulmonary, renal, metabolic, or immunosuppressive conditions are associated with severe disease and higher mortality.

The case-level details recorded in the surveillance data illustrate the heterogeneity within this small series. The first case, a man aged 50 to 59 years in Al Jouf with comorbidities, developed symptoms on 14 March 2026 and was confirmed by RT-PCR on 19 March, with no direct camel contact reported. The second case, a man aged 70 or older in Taif with comorbidities, had symptom onset on 18 April, confirmation on 22 April, and died. Only two of the eight cases, one in Hafr Al-Batin in May and one in Arar in September, reported direct camel contact. The remaining cases, including a woman aged 70 or older in Riyadh, a man aged 30 to 39 years in Riyadh without comorbidities, and further cases in Tabuk and Taif, all reported no direct camel contact. For most patients the outcome was not specified in the available data.

One case, however, departed from the classic profile: severe disease occurred in a younger patient without reported comorbidities. The authors of the analysis caution that a single case cannot establish any change in viral virulence or host susceptibility, but it serves as a reminder that MERS-CoV is not confined to the high-risk phenotype of older adults with chronic illness. Clinical recognition of possible MERS-CoV infection should therefore not depend exclusively on whether a patient matches the expected demographic and medical pattern, particularly when exposure histories are incomplete or unavailable.

The temporal pathway of diagnosis in this cohort reveals a critical vulnerability. The mean interval from symptom onset to hospitalization was 3.4 days, and the mean interval from hospitalization to RT-PCR confirmation was 2.4 days. Taken together, the mean interval from symptom onset to laboratory confirmation was approximately 5.8 days. This interval represents a period during which an unrecognized MERS-CoV infection may expose household members, health-care workers, and other patients before isolation and public-health investigation can be completed. Four of the eight cases occurred in August and September, but the authors urge that this apparent clustering should not be interpreted as evidence of a seasonal surge. With only eight cases, temporal clustering may reflect chance variation, surveillance intensity, health-care-seeking behavior, or changes in human-animal contact patterns. The more important observation is the roughly six-day diagnostic delay itself, which creates a window for unrecognized transmission.

To frame the central problem, the analysis proposes that cryptic exposure-unlinked cases be defined as laboratory-confirmed MERS-CoV infections in which routine epidemiological investigation does not identify direct or indirect camel exposure, a known symptomatic contact, or a clear health-care exposure. In this cohort, six of the eight cases reported no direct camel contact. This proportion is striking but requires careful interpretation. No known camel exposure is not equivalent to no exposure. Patients may not recall brief contact with camels, contaminated environments, raw camel milk, or other camel-derived products, and exposure information may be incomplete when interviews occur after hospitalization or during severe illness.

The most plausible interpretation, according to the authors, is that many exposure-unlinked cases represent unrecognized indirect zoonotic or environmental exposure rather than a newly dominant mode of human-to-human transmission. Current evidence continues to support direct contact with infected camels and symptomatic human cases as the major transmission routes, while the role of asymptomatic individuals in transmission remains uncertain. Health-care-associated exposure also remains an important consideration, because MERS-CoV has repeatedly caused nosocomial clusters when clinical recognition, diagnostic testing, or infection prevention and control measures were delayed. The analysis lays out a hierarchy of explanations, ranking unrecognized indirect camel or environmental exposure and incomplete recall or ascertainment as highly plausible, health-care-associated exposure as moderately to highly plausible, undetected mild or asymptomatic human transmission as possible but unproven, and alternative reservoirs or vectors as speculative, since dromedary camels remain the best-supported reservoir.

The case series also enters the difficult territory of MERS-CoV mortality statistics. The global reported case fatality ratio for MERS-CoV is approximately 36 percent among laboratory-confirmed cases, but the authors emphasize that this estimate should not be interpreted as the probability of death following infection. Three distinct measures must be separated: the confirmed-case fatality ratio, calculated as deaths divided by laboratory-confirmed cases; the infection fatality ratio, calculated as deaths divided by all infections including mild and asymptomatic cases; and hospitalized-case mortality among severe, hospitalized patients. A recent reassessment illustrates how strongly mortality estimates depend on the population studied and the ascertainment framework used. In a prospective Saudi cohort of 6,873 individuals investigated for MERS-CoV between 2014 and 2019, mortality among the 501 laboratory-confirmed cases was approximately 21 percent, substantially below the cumulative global case fatality ratio of 36 percent. That gap reflects differences in denominators and detection rather than a true change in virulence.

Comorbidities appear to stratify risk further among confirmed cases. In one study, diabetes, hypertension, and cardiovascular disease were associated with case fatality rates of 32 percent, 35 percent, and 39 percent, respectively, compared with lower rates among patients without these conditions. This pattern reinforces the need for heightened clinical vigilance and early supportive care in patients with chronic cardiometabolic disease. The authors note that seroprevalence studies, active household investigations, and systematic testing of contacts remain needed to quantify the unseen fraction of infections and refine estimates of the true infection fatality ratio, which depends on identifying mild and asymptomatic infections that never enter routine case counts.

The 2026 experience supports several practical priorities. MERS-CoV testing should be considered for severe acute respiratory infections when clinically and epidemiologically appropriate, even when no animal exposure is initially reported. Rapid molecular testing, clear testing algorithms, and easy laboratory access can reduce the interval between admission and confirmation. Suspected MERS-CoV should be managed with appropriate infection prevention and control precautions until results are available, particularly in emergency departments and intensive care units. Case investigations should systematically explore direct and indirect camel contact, raw camel-product consumption, animal markets, farms, household contacts, recent health-care exposure, and travel. Human surveillance should also be linked with camel surveillance, environmental sampling where feasible, and genomic sequencing to identify transmission links and viral lineages. Targeted seroprevalence studies in high-exposure occupational groups and selected urban communities can help define the true infection burden and clarify whether subclinical infections contribute materially to transmission. From a surveillance-policy perspective, the exposure-ascertainment gap identified in this case series is framed as a structural signal for Saudi Arabia’s broader MERS-CoV reporting architecture rather than merely a clinical finding. Under the Kingdom’s International Health Regulations (2005) obligations and the national notifiable disease framework, case investigation currently relies heavily on retrospective patient and family recall obtained after hospitalization, often during severe illness, which may systematically bias exposure data toward incompleteness. Closing this gap, the authors argue, requires institutionalizing structured, standardized exposure-interview protocols at first clinical contact, before diagnostic confirmation, and formally linking human case surveillance with camel-health surveillance data and environmental sampling programs. Such integration, rather than incremental improvements to individual case investigations, is presented as the more durable solution to resolving exposure-unlinked status and should be prioritized as national health policy. The 2026 cases do not signal a new pandemic phase of MERS-CoV, but they reinforce an enduring lesson: low reported case numbers do not equal low risk. Cryptic, in this context, is appropriate only when defined as unresolved exposure after investigation. The next step is not to assume silent community transmission, but to measure it through better case investigation, earlier testing, stronger infection prevention, integrated One Health surveillance, and carefully designed seroprevalence studies.

Subject of Research: Epidemiology of exposure-unlinked laboratory-confirmed MERS-CoV cases in Saudi Arabia in 2026

Article Title: "Cryptic" MERS-CoV: insights from eight Saudi Arabian cases in 2026 with no camel exposure

Article References: Al-Tawfiq, J. A., & Assiri, A. M. (2026). "Cryptic" MERS-CoV: insights from eight Saudi Arabian cases in 2026 with no camel exposure. New Microbes and New Infections, Article 101875. https://doi.org/10.1016/j.nmni.2026.101875

Image Credits: AI Generated

DOI: 10.1016/j.nmni.2026.101875

Keywords: MERS-CoV, Saudi Arabia, zoonotic disease, dromedary camels, exposure ascertainment, surveillance, case fatality ratio, nosocomial transmission, One Health, seroprevalence, RT-PCR, public health